WO1998017315A3 - Permeation enhancers for transdermal drug delivery compositions, devices, and methods - Google Patents

Permeation enhancers for transdermal drug delivery compositions, devices, and methods Download PDF

Info

Publication number
WO1998017315A3
WO1998017315A3 PCT/US1997/018956 US9718956W WO9817315A3 WO 1998017315 A3 WO1998017315 A3 WO 1998017315A3 US 9718956 W US9718956 W US 9718956W WO 9817315 A3 WO9817315 A3 WO 9817315A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
permeation enhancer
methods
drug delivery
devices
Prior art date
Application number
PCT/US1997/018956
Other languages
French (fr)
Other versions
WO1998017315A2 (en
Inventor
Eun Soo Lee
Su Il Yum
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to CA002264687A priority Critical patent/CA2264687C/en
Priority to EP97912815A priority patent/EP0934078B1/en
Priority to DK97912815T priority patent/DK0934078T3/en
Priority to DE69718037T priority patent/DE69718037T2/en
Priority to JP10519563A priority patent/JP2001502693A/en
Priority to AU49907/97A priority patent/AU4990797A/en
Priority to AT97912815T priority patent/ATE229817T1/en
Publication of WO1998017315A2 publication Critical patent/WO1998017315A2/en
Publication of WO1998017315A3 publication Critical patent/WO1998017315A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in drug- and- permeation enhancer- transmitting relation with a skin site. The matrix contains sufficient amounts of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compositions and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers.
PCT/US1997/018956 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods WO1998017315A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002264687A CA2264687C (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
EP97912815A EP0934078B1 (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DK97912815T DK0934078T3 (en) 1996-10-24 1997-10-23 Permeability promoters for transdermal administration of active substances, devices and processes for their preparation
DE69718037T DE69718037T2 (en) 1996-10-24 1997-10-23 PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES, DEVICES AND METHODS FOR THE PRODUCTION THEREOF
JP10519563A JP2001502693A (en) 1996-10-24 1997-10-23 Permeation enhancers suitable for transdermal drug administration compositions, devices, and methods
AU49907/97A AU4990797A (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods
AT97912815T ATE229817T1 (en) 1996-10-24 1997-10-23 PENETRATION-PROMOTING SUBSTANCES FOR THE TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS, DEVICES AND METHOD FOR THE PRODUCTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3042496P 1996-10-24 1996-10-24
US60/030,424 1996-10-24

Publications (2)

Publication Number Publication Date
WO1998017315A2 WO1998017315A2 (en) 1998-04-30
WO1998017315A3 true WO1998017315A3 (en) 1998-07-02

Family

ID=21854141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018956 WO1998017315A2 (en) 1996-10-24 1997-10-23 Permeation enhancers for transdermal drug delivery compositions, devices, and methods

Country Status (10)

Country Link
US (1) US6004578A (en)
EP (1) EP0934078B1 (en)
JP (1) JP2001502693A (en)
AT (1) ATE229817T1 (en)
AU (1) AU4990797A (en)
CA (1) CA2264687C (en)
DE (1) DE69718037T2 (en)
DK (1) DK0934078T3 (en)
ES (1) ES2191834T3 (en)
WO (1) WO1998017315A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518417A (en) * 1998-06-25 2002-06-25 ラヴィファム ラボラトリーズ インコーポレーテッド Braces and methods for treating erectile dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
IL144755A0 (en) 1999-02-08 2002-06-30 Alza Corp Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7378108B1 (en) 1999-02-19 2008-05-27 Takeda Pharmaceutical Company Limited Percutaneous absorption preparation of compound having angiotensin II antagonistic activity
AU6595100A (en) 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
RU2708563C2 (en) * 2001-03-16 2019-12-10 Алза Корпорейшн Transdermal patch for administering fentanyl
US6521613B2 (en) 2001-04-10 2003-02-18 Allergan, Inc. Lactam compounds for penetration enhancement
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
EP1390085B1 (en) 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Hydrogel compositions
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
EP1390084B1 (en) 2001-05-01 2011-03-23 A.V. Topchiev Institute of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
DE10154324A1 (en) * 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topically applicable compositions with external active substance depot formation, their production and their use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CN1720028A (en) 2002-04-23 2006-01-11 阿尔扎公司 Transdermal analgesic systems with reduced abuse potential
US20040033255A1 (en) 2002-06-10 2004-02-19 Baker Carl J. Transdermal delivery device disposal system
ATE423560T1 (en) * 2002-08-20 2009-03-15 Euro Celtique Sa TRANSDERMAL DOSAGE FORM CONTAINING AN ACTIVE INGREDIENT AND AN ANTAGONIST IN FREE BASE AND IN SALT FORM
CN100340395C (en) * 2002-08-30 2007-10-03 阿尔扎公司 Multilaminate backing construction
US20040057907A1 (en) * 2002-09-23 2004-03-25 Leonard Mackles Dri-nasal sprays
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd Transdermal delivery system for anti-emetic medication
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040202708A1 (en) * 2003-04-14 2004-10-14 3M Innovative Properties Company Transdermal drug delivery device with translucent inorganic barrier layer
BRPI0409945A (en) 2003-04-30 2006-04-25 Purdue Pharma Lp change resistant dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219198A1 (en) * 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing
US7563748B2 (en) * 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1648363B1 (en) 2003-07-03 2019-03-06 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
CA2534238A1 (en) 2003-07-28 2005-02-10 Alza Corporation Transdermal warfarin-containing delivery system
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
CA2543610A1 (en) 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
WO2005074894A1 (en) 2004-01-30 2005-08-18 Corium International Rapidly dissolving film for delivery of an active agent
MX2007001512A (en) 2004-08-05 2007-04-20 Corium Int Inc Adhesive composition.
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
ATE438664T1 (en) * 2004-10-19 2009-08-15 3M Innovative Properties Co METHOD FOR PRODUCING PRESSURE-SENSITIVE ADHESIVES
EP2216018B1 (en) 2004-10-21 2012-04-04 Durect Corporation Transdermal delivery systems
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20060216350A1 (en) * 2005-03-24 2006-09-28 Dow Gordon J Ganglionic blocking agents for the treatment of epithelial diseases
PL1895994T3 (en) * 2005-05-13 2011-02-28 Alza Corp Multilayer drug delivery system with barrier against reservoir material flow
ATE539740T1 (en) 2005-06-10 2012-01-15 3M Innovative Properties Co METHOD FOR HANDLING ADHESIVE LAMINATE SECTIONS
US8383149B2 (en) * 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
EP1951186A4 (en) 2005-10-19 2009-11-04 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
US9909098B2 (en) 2007-08-06 2018-03-06 The Regents Of The University Of California Methods of tissue-based diagnosis
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
CN104398496B (en) * 2007-10-15 2018-03-20 阿尔扎公司 Change a transdermal administration in one day of fentanyl
MX2011002260A (en) * 2008-09-30 2011-04-07 Teikoku Pharma Usa Inc Transdermal extended-delivery donepezil compositions and methods for using the same.
EP2387394B1 (en) 2009-01-14 2018-05-02 Corium International, Inc. Transdermal administration of tamsulosin
CN104523661A (en) * 2009-02-06 2015-04-22 南加利福尼亚大学 Therapeutic compositions comprising monoterpenes
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
JP2013512257A (en) 2009-11-30 2013-04-11 スリーエム イノベイティブ プロパティズ カンパニー Compatible barrier sheet, method and article
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103619338B (en) * 2011-03-31 2016-06-22 阿索尔达治疗有限公司 Intranasal benzodiazepine pharmaceutical composition
WO2013090353A1 (en) 2011-12-16 2013-06-20 3M Innovative Properties Company Foldable adhesive composite dressing
US10426739B2 (en) 2011-12-21 2019-10-01 3M Innovative Properties Company Adhesive patch assembly with overlay liner and system and method for making same
EP2793869B1 (en) 2011-12-21 2015-09-23 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
WO2013172832A1 (en) * 2012-05-16 2013-11-21 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
EP2906284B8 (en) 2012-10-10 2021-01-20 Kindeva Drug Delivery L.P. Force-controlled applicator for applying a microneedle device to skin
EP2919849B1 (en) 2012-11-16 2021-01-06 Kindeva Drug Delivery L.P. Force-controlled applicator for applying a microneedle device to skin
JP2016517707A (en) 2013-03-22 2016-06-20 スリーエム イノベイティブ プロパティズ カンパニー Microneedle applicator with counter assembly
KR102274902B1 (en) 2013-05-31 2021-07-07 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle injection and infusion apparatus and method of using same
KR101615592B1 (en) 2013-05-31 2016-04-26 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle injection apparatus comprising an inverted actuator
WO2014193727A1 (en) 2013-05-31 2014-12-04 3M Innovative Properties Company Microneedle injection apparatus comprising a dual cover
WO2015023649A2 (en) 2013-08-12 2015-02-19 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3020398A1 (en) 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
US10478346B2 (en) 2014-12-18 2019-11-19 3M Innovative Properties Company Methods of handling adhesive laminate patches
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
CA2994702A1 (en) 2015-08-05 2017-02-09 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
US20210100754A1 (en) 2016-02-05 2021-04-08 3M Innovative Properties Company Transdermal drug delivery systems with fluorosilicone release liners
US11021430B2 (en) 2016-04-05 2021-06-01 Moresco Corporation Oxa acid compound
BR112018073511A2 (en) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. glucagon receptor selective polypeptides and methods of use
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
US10016372B2 (en) 2016-07-27 2018-07-10 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
JP7251033B2 (en) 2016-07-27 2023-04-04 コリウム, エルエルシー Donepezil transdermal delivery system
EP3287462A1 (en) 2016-08-25 2018-02-28 Nitto Denko Corporation Isosorbide derivatives to treat bacterial biofilms
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
EP3590540A4 (en) * 2017-03-03 2021-01-20 Moresco Corporation Absorption promoter and use for same
AU2018392686A1 (en) 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
DK3749291T3 (en) 2018-02-08 2024-04-08 Univ Southern California METHODS OF PERMEABILIZING THE BLOOD-BRAIN BARRIER
WO2019194871A1 (en) * 2018-04-05 2019-10-10 Erbst Steven Robert Therapeutic elastic bandage for modulating the endocannabinoid system
US20210228556A1 (en) * 2018-05-08 2021-07-29 University Of Connecticut Long-acting local anesthetic formulation
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
EP4003256A4 (en) * 2019-07-30 2023-05-24 Kai P. Leung Layered composite for scar treatment and prevention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020378A1 (en) * 1991-05-15 1992-11-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Penetration-promoting substance
WO1996019976A1 (en) * 1994-12-24 1996-07-04 Pacific Corporation Medicinal patches for percutaneous administration
WO1996040139A1 (en) * 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1011949A (en) * 1964-10-27 1965-12-01 Vacu Blast Ltd Centrifugal wheel blasting machine
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3731663A (en) * 1971-01-08 1973-05-08 Hollins J R Vehicle engine fuel control accelerator override
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4130643A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
FR2495934A1 (en) * 1980-12-15 1982-06-18 Cird COMPOSITION FOR THE TREATMENT OF PSORIASIS BASED ON SUBSTITUTED-1,8-DIHYDROXY-1,8-ANTHRONE-9
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4573999A (en) * 1983-10-14 1986-03-04 Netto Daniel J Human breast prosthesis
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4900555A (en) * 1987-02-26 1990-02-13 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4865848A (en) * 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
JP2820306B2 (en) * 1990-02-27 1998-11-05 積水化学工業株式会社 Transdermal formulation
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
WO1993023025A1 (en) * 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
JP3792252B2 (en) * 1993-09-29 2006-07-05 アルザ・コーポレーション Monoglyceride / lactate ester permeation enhancer for oxybutynin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020378A1 (en) * 1991-05-15 1992-11-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Penetration-promoting substance
WO1996019976A1 (en) * 1994-12-24 1996-07-04 Pacific Corporation Medicinal patches for percutaneous administration
WO1996040139A1 (en) * 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KADIR R. ET AL: "Penetration of theophylline and adenosine into excised human skin from binary and ternary vehicles: effect of a nonionic surfactant", J. OF PHARM. SCIENCES, vol. 78, no. 2, 1989, pages 149 - 153, XP002063173 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
AU4990797A (en) 1998-05-15
EP0934078B1 (en) 2002-12-18
ATE229817T1 (en) 2003-01-15
DE69718037D1 (en) 2003-01-30
DE69718037T2 (en) 2003-07-10
US6004578A (en) 1999-12-21
JP2001502693A (en) 2001-02-27
CA2264687C (en) 2006-04-25
WO1998017315A2 (en) 1998-04-30
ES2191834T3 (en) 2003-09-16
CA2264687A1 (en) 1998-04-30
DK0934078T3 (en) 2003-04-14
EP0934078A2 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
AU4990797A (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
MX9709162A (en) Skin permeation enhancer compositions using acyl lactylates.
ES2137261T3 (en) TRANSDERMIC ADMINISTRATION OF OXYBUTININE.
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
FR11C0006I1 (en) IMPROVED DRUG DELIVERY ON MUCOSA
ZA944608B (en) Incorporating poly-N-vinyl amide in a transdermal system
MX9602656A (en) Transdermal device containing polyvinylpyrrolidone as solubility enhancer.
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
CA2333076A1 (en) Topical application of muscarinic analgesic drugs such as neostigmine
HK1036594A1 (en) Formulations for the transdermal administration offenoldopam.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264687

Country of ref document: CA

Ref country code: CA

Ref document number: 2264687

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 519563

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997912815

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912815

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997912815

Country of ref document: EP